Highlights:
-Physicians for Integrity in Medical Research says in its federal complaint against Food and Drug Administration Commissioner Margaret Hamburg
– best-case scenario showed that roflumilast reduced the number of exacerbations by one episode a year for every five patients treated
– the regulator ignored the “statistically significant increase in incidents of prostate and lung cancer in patients taking roflumilast.”
———- Possible safe Option Vinpocetine
-Published today in the Proceedings of the National Academy of Sciences vinpocetine has great potential for the treatment of COPD and other inflammatory diseases.”
-has no evidence of toxicity or noticeable side effects in human patients
http://healthresearchreport.me/2012/11/20/purple-periwinkles-battle-inflammatory-diseases-copd/
